Ratings coverage on Celldex Therapeutics Inc (NASDAQ: CLDX), Immunomedics Incorporated (NASDAQ: IMMU), YPF Sociedad Anonima (NYSE: YPF), CVR Partners (NYSE: UAN) and Cintas (NASDAQ: CTAS) was initiated by analysts this week.
Oppenheimer initiated coverage on Celldex Therapeutics Inc (CLDX). They placed an “outperform” rating and a price target of $6.00 on the company.
Oppenheimer initiated coverage on shares of Immunomedics Incorporated (IMMU). They placed an “outperform” rating and a price target of $6.00 on the company.
Raymond James (NYSE:RJF) initiated coverage on YPF Sociedad Anonima (YPF). They placed an “outperform” rating on the company.
Goldman Sachs (NYSE:GS) initiated coverage on shares of CVR Partners (UAN). They placed a “neutral” rating on the company.
Stifel Nicolaus initiated coverage on Cintas (CTAS). They placed a “hold” rating and a price target of $30.70 on the company.
Showing posts with label Celldex Therapeutics. Show all posts
Showing posts with label Celldex Therapeutics. Show all posts
Saturday, May 21, 2011
Tuesday, May 17, 2011
Coverage on (AMAP) (ANTH) (ATRO) (CLDX) (CTAS) Initiated
Coverage on AutoNavi Holdings Ltd (NASDAQ: AMAP), Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), Astronics Co. (NASDAQ: ATRO), Celldex Therapeutics Inc (NASDAQ: CLDX) and Cintas (NASDAQ: CTAS) was initiated by analysts.
Deutsche Bank (NYSE:DB) initiated coverage on AutoNavi Holdings Ltd (AMAP). They placed a “buy” rating and a price target of $22.00 on the company.
Leerink initiated coverage on Anthera Pharmaceuticals, Inc. (ANTH). They placed an “outperform” rating on the company.
EarlyBird Capital initiated coverage on Astronics Co. (ATRO). They placed a “hold” rating on the company.
Oppenheimer initiated coverage on Celldex Therapeutics Inc (CLDX). They placed an “outperform” rating and a price target of $6.00 on the company.
Stifel Nicolaus initiated coverage on Cintas (CTAS). They placed a “hold” rating and a price target of $30.70 on the company.
Deutsche Bank (NYSE:DB) initiated coverage on AutoNavi Holdings Ltd (AMAP). They placed a “buy” rating and a price target of $22.00 on the company.
Leerink initiated coverage on Anthera Pharmaceuticals, Inc. (ANTH). They placed an “outperform” rating on the company.
EarlyBird Capital initiated coverage on Astronics Co. (ATRO). They placed a “hold” rating on the company.
Oppenheimer initiated coverage on Celldex Therapeutics Inc (CLDX). They placed an “outperform” rating and a price target of $6.00 on the company.
Stifel Nicolaus initiated coverage on Cintas (CTAS). They placed a “hold” rating and a price target of $30.70 on the company.
Thursday, January 6, 2011
Celldex Therapeutics (NASDAQ:CLDX) Rindopepimut in GBM Looks Promising
Celldex Therapeutics (NASDAQ:CLDX) is expected sometime in the early part of 2011 to finalize a key study for rindopepimut in GBM, which could lead to an SPA.
Needham said, "Looking into 2011, the Company expects to meet with the FDA in early 2011 to finalize a pivotal study for rindopepimut in GBM, which may lead to a SPA, and plans to initiate an international, randomized, placebo controlled Phase 3 trial in 2H11. We believe that rindopepimut has demonstrated consistent efficacy in GBM in three Phase 2 trials and has built a compelling database to support the pivotal trial. With the return of the rights of rindopepimut from Pfizer (N/R), we believe the program may accelerate, as Celldex is fully committed to move rindopepimut forward expediently."
Needham & Company maintains a "Buy" rating on Celldex Therapeutics, which closed Wednesday at $4.18, up $0.04, or 0.97 percent.
Needham said, "Looking into 2011, the Company expects to meet with the FDA in early 2011 to finalize a pivotal study for rindopepimut in GBM, which may lead to a SPA, and plans to initiate an international, randomized, placebo controlled Phase 3 trial in 2H11. We believe that rindopepimut has demonstrated consistent efficacy in GBM in three Phase 2 trials and has built a compelling database to support the pivotal trial. With the return of the rights of rindopepimut from Pfizer (N/R), we believe the program may accelerate, as Celldex is fully committed to move rindopepimut forward expediently."
Needham & Company maintains a "Buy" rating on Celldex Therapeutics, which closed Wednesday at $4.18, up $0.04, or 0.97 percent.
Tuesday, November 23, 2010
Needham Maintains "Buy on Celldex (NASDAQ:CLDX) on Rindopepimut Potential
After unveiling the Phase 2 results concerning cancer vaccine "rindopepimut" at a recent Montreal SNO meeting, Needham reiterated their "Buy" rating on Celldex Therapeutics (NASDAQ:CLDX).
"We believe that the ACT III multicenter data are consistent with two other previously completed Phase 2 trials and further confirm the efficacy of the active immunotherapeutic (cancer vaccine) rindopepimut and support pivotal testing in GBM. The Company expects to meet with the FDA in early 2011 to finalize a pivotal study, which may lead to a SPA, and plans to initiate an international, randomized, placebo controlled Phase 3 trial in 2H11," said Needham.
Celldex closed Monday at $4.30, dropping $0.32, or 6.93 percent. Needham has a price target of $12 on the company.
"We believe that the ACT III multicenter data are consistent with two other previously completed Phase 2 trials and further confirm the efficacy of the active immunotherapeutic (cancer vaccine) rindopepimut and support pivotal testing in GBM. The Company expects to meet with the FDA in early 2011 to finalize a pivotal study, which may lead to a SPA, and plans to initiate an international, randomized, placebo controlled Phase 3 trial in 2H11," said Needham.
Celldex closed Monday at $4.30, dropping $0.32, or 6.93 percent. Needham has a price target of $12 on the company.
Subscribe to:
Posts (Atom)